A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Prior treatment

• Have received prior systemic therapy for locally advanced or metastatic urothelial cancer (mUC).
• Have any unresolved toxicities greater than Grade 1 Common Terminology Criteria for Adverse Events (\[CTCAE\] version 5.0) from prior neoadjuvant or adjuvant systemic therapy.

Other illness

• Have untreated or uncontrolled central nervous system (CNS) involvement or any history of leptomeningeal disease.
• Current evidence corneal keratopathy or retinal disorder confirmed by ocular examination at screening.

Other

• Have ongoing sensory or motor neuropathy of Grade 2 or higher

• Have histologically confirmed, unresectable locally advanced or metastatic urothelial cancer (mUC). Individuals with mixed histology other than small cell or neuroendocrine carcinoma are eligible if a urothelial component is present.
• Have a qualifying fibroblast growth factor receptor 3 (FGFR3) genetic alteration determined via molecular testing from a tumor or blood sample obtained at or any time after diagnosis of advanced or metastatic urothelial cancer.
• Have measurable disease by investigator assessment defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
• Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
• Have adequate laboratory parameters